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Abstract
Background: Sterol biosynthesis is an essential pathway for fungal survival, and is the biochemical target of many
antifungal agents. The antifungal drugs most widely used to treated fungal infections are compounds that inhibit
cytochrome P450-dependent C14a-demethylase (CYP51), but other enzymes of this pathway, such as squalene
synthase (SQS) which catalyses the first committed step in sterol biosynthesis, could be viable targets. The aim of
this study was to evaluate the antifungal activity of SQS inhibitors on Candida albicans, Candida tropicalis and
Candida parapsilopsis strains.
Methods: Ten arylquinuclidines that act as SQS inhibitors were tested as antiproliferative agents against three
ATCC strains and 54 clinical isolates of Candida albicans, Candida tropicalis and Candida parapsilopsis. Also, the
morphological alterations induced in the yeasts by the experimental compounds were evaluated by fluorescence
and transmission electron microscopy.
Results: The most potent arylquinuclidine derivative (3-[1’-{4’-(benzyloxy)-phenyl}]-quinuclidine-2-ene) (WSP1267)
had a MIC50 of 2 μg/ml for all species tested and MIC90 varying from 4 μg/ml to 8 μg/ml. Ultrathin sections of
C. albicans treated with 1 μg/ml of WSP1267 showed several ultrastructural alterations, including (a) loss of cell wall
integrity, (b) detachment of the plasma membrane from the fungal cell wall, (c) accumulation of small vesicles in
the periplasmic region, (d) presence of large electron-dense vacuoles and (e) significantly increased cell size and
cell wall thickness. In addition, fluorescence microscopy of cells labelled with Nile Red showed an accumulation of
lipid droplets in the cytoplasm of treated yeasts. Nuclear staining with DAPI revealed the appearance of
uncommon yeast buds without a nucleus or with two nuclei.
Conclusion: Taken together, our data demonstrate that arylquinuclidine derivatives could be useful as lead
compounds for the rational synthesis of new antifungal drugs.
Background
Candidiasis is the most common fungal infection; it is
found all over the world. Candida spp. isolates are the
fourth most common microorganisms found in blood-
stream infections and are particularly prevalent among
patients hospitalised for long periods who have been
exposed to antibiotics, immunosuppressive therapy,
parenteral nutrition, and multiple invasive medical pro-
cedures [1]. Systemic fungal infections are generally dif-
ficult to diagnose and hard to treat, having an
attributable mortality rate of near 40% [1]. Although
Candida albicans is the species most frequently isolated
from those patients, being responsible for more than
half of candidiasis cases, the incidence of other species,
such as Candida parapsilopsis and Candida tropicalis,i s
increasing [2].
Most current therapies to treat fungal infections are
based on disrupting fungal membrane homeostasis. The
most commonly used groups of antifungal agents are
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brane function by direct association with fungal sterols,
and the azoles (fluconazole, itraconazole, voriconazole
and posaconazole), which inhibit sterol biosynthesis in a
step catalysed by the cytochrome P450-dependent
C14a-demethylase [3]. Treatment of invasive Candida
infections is often complicated by high toxicity, low toler-
ability or a narrow spectrum of activity of the current
antifungal drugs as well as an increase in the incidence of
azole-resistant strains [4]. These difficulties have driven
the search for new treatments with different mode(s) of
action.
Squalene synthase (SQS) is a key enzyme in sterol bio-
synthesis that catalyses an unusual head-to-head conden-
sation of two molecules of farnesyl pyrophosphate in a
two-step reaction to produce squalene, which is the first
committed step in sterol biosynthesis. Importantly, inhibi-
tion of this enzyme does not affect the biosynthesis of
other essential isoprenoids derived from farnesyl pyro-
phosphate derivatives, such as ubiquinones, dolichols,
haeme, and C15-o rC 20-isoprenoid chains [5]. In recent
years, significant effort has been devoted to evaluating
SQS with the aim of developing new cholesterol-lowering
agents in mammalian cells [6]. Several classes of com-
pound have been developed, including arylquinuclidines
[7] and zaragozic acids. In addition, arylquinuclidine
compounds have potent activity in concentrations varying
from the nanomolar to subnanomolar range against para-
sitic protozoa, such as Trypanosoma cruzi, Leishmania
and Toxoplasma gondii [8-12]. Zaragozic acids show
significant activity against various fungal species [13].
In this work, the antifungal effect of the prototypical
arylquinuclidine molecule BPQ-OH {3-(biphenyl-4-yl)-3-
hydroxyquinuclidine or 3-biphenyl-4-yl-1-aza-bicyclo
[2,2,2]-octan-3-ol} and 9 derivatives was evaluated
against three ATCC strains and 54 clinical isolates of
C. albicans, C. parapsilosis and C. tropicalis.F i v e
aspects of the antifungal effects of these compounds
were investigated: (i) growth inhibition, (ii) fungicidal
effect, (iii) morphological alterations, (iv) lipid accumula-
tion and (v) cell cycle alteration.
Methods
Drugs
The prototypical arylquinuclidine BPQ-OH was prepared
as described by Brown et al. [14]. Nine analogues
(WSP1261, WSP1262, WSP1263, WSP1264, WSP1265,
WSP1266, WSP1267, WSP1268 and WSP1269) (Figure
1) that are active against Leishmania major and selective
to the parasite’s SQS over the human enzyme [15] were
also tested. Fluconazole, itraconazole, and amphotericin B
were used as standard antifungal drugs. The compounds
were diluted in DMSO, except fluconazole, which was
diluted in water. They were then maintained at -20°C.
Yeast collection
To evaluate the antifungal activity of the synthetic aryl-
quinuclidine derivatives, three standard strains from the
American Type Culture Collection (ATCC) were used
for screening: Candida albicans ATCC 10231, Candida
parapsilosis ATCC 22019 and Candida tropicalis ATCC
13803. In addition, 54 clinical isolates of Candida were
evaluated for high antifungal activity compounds: Can-
dida albicans (n = 21), Candida parapsilosis (n = 19),
and Candida tropicalis (n = 14). These strains were iso-
lated between 2002 and 2006 at the Microbiology/
Mycology Laboratory of Hemorio, Rio de Janeiro, Brazil,
and kindly provided by Marcos Dornelas Ribeiro. The
yeasts were maintained on Sabouraud dextrose agar at
4°C, and subcultures were performed prior to each
experiment in the same medium for 48 h at 35°C.
Antifungal activity assays
Minimum inhibitory concentration (MIC) assays were
performed using a broth microdilution method adapted
from the M27-A3/CLSI document [16]. Briefly, each
compound was diluted in RPMI 1640 medium (Sigma
Chemical Co., Missouri, USA), buffered with MOPS
0.16 M, pH 7.0, diluted in a 96-well microtitre tray and
added to the growth medium to obtain the following
final concentrations: 0.03-16 μg/ml (arylquinuclidines
and itraconazole), 0.25-128 μg/ml (fluconazole) and
0.007-4 μg/ml (amphotericin B). Yeasts were then added
to each well at the final concentration of 0.5-2.5 × 10
3
cfu/ml. The microtitre trays were incubated at 35°C for
48 h in a dark, humid chamber. Afterwards, IC50 values
(the lowest concentrations that inhibit 50% of the yeast
growth in comparison to control) for each compound
were determined using a spectrophotometer at 492 nm.
To determine the trailing effect in Candida strains (per-
sistent growth of some isolates of Candida in drug con-
centrations above the IC50 after 48 h of incubation,
commonly observed in broth microdilution tests with
azole agents) visual reading was performed after 24 and
48 h of incubation. MIC50 and MIC90 values (minimum
inhibitory concentration required to inhibit the growth
of 50% and 90% of the population of each Candida spe-
cies with n ≥ 10, respectively) were also determined for
standard drugs. Only arylquinuclidine derivatives that
showed antifungal activity lower than 16 μg/mL for
ATCC strains were evaluated against the 54 clinical iso-
lates. This breakpoint was selected because is the
recommended concentration for the evaluation of new
azoles without previously defined breakpoints [16].
Minimum fungicidal concentrations (MFC) were
determined by transferring an aliquot (10 μl) of each
sample treated with concentrations higher than the IC50
onto a drug-free Sabouraud dextrose agar plate and
incubated at 35°C for 48 h. MFC means the lowest
Ishida et al. Annals of Clinical Microbiology and Antimicrobials 2011, 10:3
http://www.ann-clinmicrob.com/content/10/1/3
Page 2 of 10concentration of compound that produces no fungal
growth. A fungicidal effect was considered when the
MFC value was equal to or up to four times the IC50
value. Above this value, the antifungal effect was consid-
ered fungistatic [17].
Fluorescence microscopy
C. albicans isolate 77 was chosen for all morphological
analyses because this strain was susceptible to all stan-
dard antifungal drugs and had the median IC50 value for
WSP1267 (1 μg/ml) of all the fungal populations tested.
C. albicans isolate 77 untreated and treated with the IC50
of WSP1267 for 48 h at 35°C were washed in PBS, pH
7.2, fixed with 4% paraformaldehyde in PBS for 30 min,
adhered to glass coverslips, covered with poly-L-lysine
and incubated with different fluorophores: (a) 5 μg/ml
Nile Red (Fluka, USA), a fluorescent lipophilic stain, for
30 min; or (b) 1 μg/ml DAPI (Sigma Chemical Co., Mis-
souri, USA), a fluorescent stain that binds strongly to
DNA, for 10 min. The coverslips were then mounted in
n-propyl gallate solution and observed under a Zeiss
Axioplan epifluorescence microscope equipped with rho-
damine (Nile Red fluorescence) and DAPI filters. Images
were recorded on a C5810 Hamamatsu camera. The
number of altered Candida was determined after count-
ing at least 300 yeasts. To analyse the effects on the cell
cycle, three morphological phases were considered:
(I) cells with one nucleus, (II) cells with one bud (daugh-
ter cell) and one nucleus in the mother cell, and (III)
cells with one bud and two nuclei (one in each cell).
Transmission electron microscopy
C. albicans isolate 77 untreated and treated with the
IC50 of WSP1267 for 48 h at 35°C were fixed in a
solution containing 2.5% glutaraldehyde and 4% freshly
prepared formaldehyde in 0.1 M cacodylate buffer (pH
7.2) for 1 h. Then yeasts were post-fixed in 0.1 M caco-
dylate buffer (pH 7.2) containing 1% osmium tetroxide,
1.25% potassium ferrocyanide and 5 mM CaCl2 for
2 hours. After that, yeasts were serially dehydrated in
ethanol and embedded in Spurr epoxy resin. Ultrathin
sections were obtained with a Leica ultramicrotome,
stained with uranyl acetate and lead citrate, and
observed under a Zeiss CEM-900 electron microscope.
Cytotoxicity assays
Green monkey kidney (Vero) cells were used for the
cytotoxicity assays. Cells were maintained in Dulbecco’s
Modified Eagle’s Medium (DMEM, Gibco Invitrogen
Corporation, New York, USA) supplemented with 2 mM
L-glutamine, 10% heat-inactivated foetal bovine serum
(FBS), and 50 μg/ml gentamicin at 37°C in a 5% CO2.
For the experiments, Vero cells (2.5 × 10
4 cells/well)
were dispensed into a 96-well microtitre tray and incu-
bated for 24 h to obtain a monolayer. Monolayers of
Vero cells were treated with concentrations of WSP1267
varying from 1 μg/ml to 40 μg/ml for 48 h at 37°C in 5%
CO2. The monolayers were fixed in 10% trichloroacetic
acid for 1 h at 4°C and stained with sulphorhodamine B
for 30 min at 4°C. The optical densities were obtained in
a spectrophotometer at 530 nm to calculate the 50%
cytotoxic concentration (CC50) [18].
Statistical analysis
Statistical analyses were performed with GraphPad
Prism 5.0 (GraphPad Software), and p < 0.05 was con-
sidered significant. Student’s t-test was used to analyse
the morphological differences between untreated and
Figure 1 Molecular structures of the arylquinuclidine derivatives used in this work. The arylquinuclidine ring is indicated by an arrow.
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was calculated to determine differences between the
MIC50 and MIC90 values
Results
Antifungal activity
Among all quinuclidines tested, WSP1267 (3-[1’-{4’-(ben-
zyloxy)-phenyl}]-quinuclidine-2-ene) exhibited the best
anti-Candida effect, with IC50 varying from 0.5 μg/ml to
8 μg/ml (C. tropicalis ATCC 13803: 0.5 μg/ml; C. albi-
cans ATCC 10231: 1 μg/ml; C. parapsilosis ATCC 22019:
8 μg/ml). All other quinuclidine analogues tested on
these three ATCC strains had IC50 values higher than
16 μg/ml.
Afterwards, the anti-Candida effect of WSP1267 was
evaluated against 54 Candida spp. clinical isolates (21
Candida albicans,1 9Candida parapsilosis and 14 Can-
dida tropicalis). Although the IC50 values varied from
0.5 μg/ml to 16 μg/ml (Table 1), the MIC50 values
(median value of each population) were the same for all
tested Candida species (2 μg/ml). MIC90 values were 4
μg/ml for C. parapsilosis,8μg/ml for C. albicans and C.
tropicalis (Table 1). For this collection of strains, C.
parapsilosis clinical isolates were more susceptible to
WSP1267 and to standard antifungal agents, especially
to itraconazole and amphotericin B, than the other two
species.
The MFC values for WSP1267 were higher than
16 μg/ml for all clinical isolates (data not shown), dis-
counting any possibility of a fungicidal aspect of this
drug.
All the clinical isolates showed similar susceptibility pro-
file to amphotericin B (IC50 range of 0.007-1 μg/ml). Two
isolates of C. tropicalis were resistant to fluconazole, while
16 exhibited trailing effects (9 C. albicans,4C. tropicalis,
and 3 C. parapsilosis). In addition, 4 isolates were resistant
to itraconazole (3 C. tropicalis and 1 C. albicans), 6 iso-
lates showed susceptibility in a dose-dependent manner
(3 C. albicans,2C. tropicalis and 1 C. parapsilosis), and
11 isolates presented trailing effects (6 C. albicans,4C.
tropicalis and 1 C. parapsilosis).
Remarkably, all isolates resistant to fluconazole (IC50
>64 μg/ml) and itraconazole (IC50 >16 μg/ml) were sus-
ceptible to WSP1267 with a mean IC50 value of 8 μg/ml.
Morphological and ultrastructural effects
Treatment of C. albicans with WSP1267 caused mor-
phological and ultrastructural effects. Fluorescence
microscopy of WSP1267-treated yeasts incubated with
Nile Red revealed an accumulation of lipid droplets in
the cytoplasm of treated yeasts when compared to
C. albicans (isolate 77) control (Figure 2A-B), indicating
that WSP1267 can induce the accumulation of lipids
and/or precursors.
Treatment with the IC50 of WSP1267 induced altera-
tions in the nuclear profile of C. albicans (Figure 3).
The treatment induced a decrease of 34% (p < 0.05) in
the number of yeasts presenting only one nucleus and
no buds (phase I), an increase of three times (p < 0.01)
in the number of yeasts with buds lacking nuclei and
only the mother cell having a nucleus (phase II) and an
increase of three times in yeasts with one bud and two
nuclei (one in each cell) (phase III), but not statistically
significant. Labelling with DAPI also revealed abnormal
chromatin condensation in approximately 11% of yeasts
(Figure 4A, white arrow), while no nucleus was observed
in 9% of yeasts (Figure 4B).
The morphological effects of the treatment with the
IC50 of WSP1267 were also evaluated using transmission
electron microscopy, which revealed that some orga-
nelles and structures could be potential targets for this
Table 1 Minimum inhibitory concentration of WSP1267,
fluconazole, itraconazole and amphotericin B against
54 Candida spp. clinical isolates
Drugs All species
(n = 54)
C.
albicans
(n = 21)
C.
parapsilosis
(n = 19)
C. tropicalis
(n = 14)
WSP1267
Range 0.5-16 0.5-8 0.5-8 2-16
Geometric
mean
2.54 2.2 2.46 3.32
MIC50 222 2
MIC90 884 8
Fluconazole
Range <0.25 to
>128
a
<0.25 to 2 <0.25 to 1 <0.25 to
>128
a
Geometric
mean
0.58 0.48 0.61 0.65
MIC50 0.25 0.25 0.5 0.5
MIC90 111 4
Itraconazole
Range <0.03 to
>16
b
<0.03 to
0.5
<0.03 to 0.5 <0.03 to
>16
b
Geometric
mean
0.05 0.09 0.05 0.05
MIC50 0.03 0.03 0.03 0.03
MIC90 0.06 0.12 0.03 0.03
Amphotericin
B
Range 0.007-0.5 0.007-0.25 0.007-0.25 0.007-0.5
Geometric
mean
0.04 0.05 0.03 0.04
MIC50 0.03 0.03 0.03 0.06
MIC90 0.12 0.12 0.25 0.12
(MIC values are expressed in μg/ml).
a Resistant (two C. tropicalis) and trailing effect (nine C. albicans, four
C. tropicalis, and three C. parapsilosis).
b Resistant (three C. tropicalis, one C. albicans), susceptibility dependence-dose
(three C. albicans, two C. tropicalis and one C. parapsilosis) and trailing effect
(six C. albicans, four C. tropicalis and one C. parapsilosis).
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untreated C. albicans showed well-preserved cells with
an external fibrillar layer (f), a compact cell wall (cw), a
plasma membrane with normal shape (cm) and a homo-
geneous cytoplasm (Figure 5A). After the treatment, dif-
ferent ultrastructural alterations were observed,
including (i) detachment of the plasma membrane from
the cell wall (Figures 5B-C, asterisks), (ii) the presence
of small vesicles in the periplasmic region (Figure 5C,
higher magnification in the inset), (iii) accumulation of
large electron-dense vacuoles in the cytoplasm (Figure
5D, v), and (iiii) disruption of the cell wall (black arrow
in Figure 5D). In addition, the loss of cell wall integrity
was also observed in the bud (Figure 5B, black arrow).
WSP1267 also induced a significant increase of cell size
of C. albicans from 4.9 ± 0.5 μm( c o n t r o lc e l l )t o5 . 9±
0.08 μm (treated cell) (p < 0.01) and cell wall thickness
from 234 ± 26 nm (control cell) to 303 ± 87 nm (trea-
ted cell) (p < 0.01).
Cytotoxicity assays
AC C 50 of 12 μg/ml was observed in Vero cells treated
with WSP1267.
Discussion
The incidence of fungal infections by Candida spp. in
Brazilian medical centres is close to 2.5 cases per 1,000
admissions; the most prevalent species is C. albicans,
followed by C. tropicalis and C. parapsilosis [1]. In addi-
tion, there is an important increase in the number of
Candida clinical isolates that are resistant to azoles, the
most important class of drugs to treat fungal infections
[1,19-21]. In our study, the percentage of fluconazole-
resistant isolates (3.7%) was lower than that observed in
other studies on Brazilian clinical isolates (5.7%) [1], iso-
lates from North America (10.2%) [19], and isolates
from Europe (5.2%) [20]. Pinto et al. [21] used 37 strains
isolated from different anatomical sites of 11 immuno-
compromised hospitalised patients infected with HIV
from the Hospital of the Federal University of Espírito
Santo (ES, Brazil) and reported four Candida strains
resistant to amphotericin B (10.8%) and two to itracona-
zole (5.4%). In our work, a higher incidence of itracona-
zole-resistant isolates (7.4%) was observed, whereas all
isolates were susceptible to amphotericin B, as shown in
previous studies [1,19,20].
Examples of recent approaches to antifungal treat-
ments include new triazoles such as ravuconazole and
albaconazole, which display a broad-spectrum activity
against yeast and filamentous fungi, including species
resistant to fluconazole and itraconazole [22]. In addi-
tion, the use of inhibitors from other steps of sterol bio-
synthesis is an alternative approach to the development
of new chemotherapeutic agents. Several inhibitors of
the mevalonate and isoprenoid pathways, as well inhibi-
tors of the steps exclusively involved in ergosterol bio-
synthesis, have been studied against fungi [23] and
parasitic protozoa [24]. For example, fluvastatin, a syn-
thetic 3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitor, developed as a cholesterol-lowering agent, has
a synergistic and fungicidal effect in combination with
fluconazole and itraconazole against C. albicans,
C. tropicalis, C. parapsilosis,a n dCryptococcus neofor-
mans, including fluconazole-resistant strains [25]. Inhi-
bitors of sterol 24-methyltransferase, an enzyme that
catalyses the incorporation of a methyl group at position
24 in the sterol side chain in fungi and trypanosomatids,
has a potent effect against different clinical isolates of
Candida spp. [26].
In the present work, we decided to investigate the
effects of arylquinuclidine-based SQS inhibitors as a
potential strategy for candidiasis treatment based on pre-
vious studies conducted with trypanosomatid parasites
[24]. BPQ-OH was one of the first arylquinuclidines (ori-
ginally developed as a potential cholesterol-lowering
agent) reported to have potent activity against the Leish-
mania major SQS [27], blocking sterol biosynthesis and
the growth of Leishmania spp. and T. cruzi in the low-
nanomolar to subnanomolar range [9-12,28]. However,
BPQ-OH is not active against Candida spp. ATCC and
clinical isolates. Therefore, we decided to test other deri-
vatives that possessed a high activity and selectivity to the
L. major enzyme over the human enzyme [15]. From the
collection of arylquinuclidine compounds investigated in
Figure 2 Differential interference contrast (DIC) microscopy (left)
and fluorescence microscopy with Nile Red (right) of C. albicans
(isolate 77) untreated (A) and treated with 1 μg/ml WSP1267
[IC50] for 48 h at 35°C (B). The treatment induced an accumulation
of lipid droplets in the cytoplasm of the yeasts (white arrows in B),
which is not present in the untreated yeasts. Bars = 5 μm.
Ishida et al. Annals of Clinical Microbiology and Antimicrobials 2011, 10:3
http://www.ann-clinmicrob.com/content/10/1/3
Page 5 of 10Figure 3 DIC microscopy (above) and fluorescence microscopy with DAPI (below) of C. albicans (isolate 77) untreated in different
phases of cell cycle. Treatment with 1 μg/ml WSP1267 [IC50] for 48 h at 35°C induced alterations in the cell cycle (white bars) in comparison
with untreated yeasts (grey bars). The graphic revealed a significant increase in the number of yeasts with alterations in the cell cycle (decrease
in phase I and increase in phases II and III). Cell cycle phases: (I) cells with one nucleus, (II) cells with bud and one nucleus in the mother cell,
and (III) cells with bud and two nuclei (one in each cell). Relevant yeast from each phase is indicated by white arrows. Bars = 5 μm; * p < 0.05;
** p < 0.01.
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spp. with MIC50 and MIC90 values of 2 and 4-8 μg/ml,
respectively. WSP1267 has also shown good potency
against the Leishmania major SQS (IC50 =0 . 1μM) and
activity against L. donovani parasites in cell culture (EC50 =
1.1 μM) [15]. Cytotoxicity studies carried out with mam-
malian cells by Cammerer et al. [15] revealed that
WSP1267 presents a 50% cytotoxic concentration of 50%
(CC50)o f1 3 . 7μg/ml (47.2 μM) to L-6 cells. Our data using
Vero cells to determine the cytotoxicity showed a similar
value (12.1 μg/ml or 41.6 μM).
To analyse morphological alterations, two different
approaches were used in this work: (i) labelling of lipid
droplets and DNA with specific fluorescent dyes (Nile
red and DAPI, respectively); and (ii) visualisation of gen-
eral ultrastructural alterations by transmission electron
microscopy. The C. albicans 77 strain was chosen for all
morphological analyses as a representative strain
because it was susceptible to all standard antifungal
drugs and presented the average WSP1267 IC50 value of
all the fungal populations tested.
The presence of lipid droplets in the treated yeasts
visualised by fluorescence microscopy using Nile Red
(Figure 2) was correlated with the presence of electron-
dense vacuoles observed by electron microscopy (Figure
5), indicating that the quinuclidine treatment may induce
an accumulation of lipid precursors in the cytoplasm
which could be interfering directly with the fungal growth.
These lipid droplets have also been observed after treat-
ment of L. amazonensis with quinuclidine derivatives, due
a total depletion of endogenous sterols and concomitant
accumulation of exogenous cholesterol, which is not suffi-
cient to maintain the viability of the parasites [10].
Recently, our group has also shown a lipid accumulation
in C. albicans clinical isolates after treatment with inhibi-
tors of 24-sterol methyltransferase, another enzyme of the
sterol biosynthesis pathway [26]. Moreover, previous stu-
dies show that it is also possible that quinuclidines inter-
fere with fatty acid and phospholipid biosynthesis, as
observed previously with mammalian cells treated with
SQS inhibitors [29] and with the trypanosomatid Chritidia
deanei after treatment with sterol 24-methyltransferase
inhibitors [30].
Analyses of the effect of WSP1267 treatment on the
C. albicans 77 isolate cell cycle revealed that the num-
ber of yeasts containing one nucleus (phase I) was sig-
nificantly reduced, with a concomitant increase in the
number of cells containing one bud and one nucleus
(phase II) and yeasts containing one bud and two nuclei
(phase III), in comparison with non-treated yeasts.
There might be two possible explanations for these phe-
notypes: (i) the cells do not complete cell division due
to alterations in the lipid composition, which is essential
for membrane structure and also for control of the cell
cycle; or (ii) the cells do not finish nuclear division, pro-
ducing buds without nuclei. Taken together with the
low MIC values and high MFC values, these data sug-
gest that the action of WSP1267 was mostly fungistatic.
Quinuclidine derivatives and 24-sterol methyltransferase
inhibitors have similar effects on the cell cycle of
L. amazonensis promastigotes [10] and Candida spp.
[26]. Moreover, previous work has demonstrated that
sterols control certain kinases involved in the cell cycle
of yeasts [31]. Some images in this study suggested that
the treated yeasts presented abnormal chromatin con-
densation, which is characteristic of apoptotic cell death.
This is consistent with a previous study demonstrating
that the deletion of the SQS gene in Saccharomyces cer-
evisiae leads to apoptotic cell death due to an impair-
ment of ergosterol biosynthesis [32].
Transmission electron microscopy revealed important
alterations in the integrity of the cell wall and plasma
membrane, which could be related to depletion of essen-
tial endogenous sterols necessary to maintain their struc-
tures. The presence of small vesicles in the periplasmic
region was also observed, as was the accumulation of
large electron-dense vacuoles, which are consistent with
the images taken by fluorescence microscopy. Similar
morphological alterations have been reported in L. ama-
zonensis treated with SQS inhibitors: an increase in the
number of lipid inclusions displaying different shapes and
electron densities, which were associated with an intense
disorganisation of the cellular membrane [10,28]. More-
over, the important ultrastructural alterations observed
in C. albicans treated with WSP1267 have been seen in
Figure 4 DIC microscopy (left) and fluorescence microscopy
with DAPI (right) of C. albicans (isolate 77) treated with 1 μg/
ml of WSP1267 [IC50] for 48 h at 35ºC, showing abnormal
chromatin condensation (A, white arrow) and absence of a
nucleus (B). Bars = 5 μm.
Ishida et al. Annals of Clinical Microbiology and Antimicrobials 2011, 10:3
http://www.ann-clinmicrob.com/content/10/1/3
Page 7 of 10C. albicans treated with 24-sterol methyltransferase inhi-
bitors [26] and are probably related to the impairment of
ergosterol biosynthesis, as has been observed after treat-
ment of L. amazonensis with other quinuclidine deriva-
tives [10,28]. Additionally, previous work has shown that
Candida spp. treated with azole agents present similar
ultrastructural alterations under transmission electron
microscopy [33-36]. Although only one C. albicans clini-
cal isolate (77) was chosen to illustrate the morphological
aspects caused by the use arylquinuclidine derivatives,
others C. albicans and non-albicans strains, including
those resistant strains to azoles, were also evaluated and
similar morphological alterations were observed (data not
shown).
Conclusion
Our results show that the arylquinuclidine derivative
WSP1267 effectively inhibited the growth of a collection
of Candida clinical isolates, including several azole-
resistant strains, probably due to impaired sterol bio-
synthesis, which led to inhibition on cell growth and the
accumulation of lipid precursors in the cytoplasm.
Although the antifungal activity of WSP1267 seems to
be due to SQS inhibition, further studies are needed to
identify the molecular target of WSP1267 in yeasts.
Additionally, we observed effects on the integrity of the
cell wall and plasma membrane and effects on the cell
cycle, which are essential for cell viability. These data
warrant further investigation of arylquinuclidines as lead
compounds for the rational synthesis of new, more
effective antifungal agents with fewer toxic effects.
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